Literature DB >> 32220387

Artificial Intelligence for Diagnosis of Acute Coronary Syndromes: A Meta-analysis of Machine Learning Approaches.

Patrick A Iannattone1, Xun Zhao2, Jacob VanHouten3, Akhil Garg4, Thao Huynh5.   

Abstract

BACKGROUND: Machine learning (ML) encompasses a wide variety of methods by which artificial intelligence learns to perform tasks when exposed to data. Although detection of myocardial infarction has been facilitated with introduction of troponins, the diagnosis of acute coronary syndromes (ACS) without myocardial damage (without elevation of serum troponin) remains subjective, and its accuracy remains highly dependent on clinical skills of the health care professionals. Application of a ML algorithm may expedite management of ACS for either early discharge or early initiation of ACS management. We aim to summarize the published studies of ML for diagnosis of ACS.
METHODS: We searched electronic databases, including PubMed, Embase, and Web of Science from inception up to January 13, 2019, for studies that evaluated ML algorithms for the diagnosis of ACS in patients presenting with chest pain. We then used random-effects bivariate meta-analysis models to summarize the studies.
RESULTS: We retained 9 studies that evaluated ML in a total of 6292 patients. The prevalence of ACS in the evaluated cohorts ranged from relatively rare (7%) to common (57%). The pooled sensitivity and specificity were 0.95 and 0.90, respectively. The positive predictive values ranged from 0.64 to 1.0, and the negative predictive values ranged from 0.91 to 1.0. The positive and negative likelihood ratios ranged from 1.6 to 33.0 and 0.01 to 0.13, respectively.
CONCLUSIONS: The excellent sensitivity, negative likelihood ratio, and negative predictive values suggest that ML may be useful as an initial triage tool for ruling out ACS.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 32220387     DOI: 10.1016/j.cjca.2019.09.013

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

1.  Quality assessment standards in artificial intelligence diagnostic accuracy systematic reviews: a meta-research study.

Authors:  Shruti Jayakumar; Viknesh Sounderajah; Pasha Normahani; Leanne Harling; Sheraz R Markar; Hutan Ashrafian; Ara Darzi
Journal:  NPJ Digit Med       Date:  2022-01-27

2.  Machine Learning Algorithms to Distinguish Myocardial Perfusion SPECT Polar Maps.

Authors:  Erito Marques de Souza Filho; Fernando de Amorim Fernandes; Christiane Wiefels; Lucas Nunes Dalbonio de Carvalho; Tadeu Francisco Dos Santos; Alair Augusto Sarmet M D Dos Santos; Evandro Tinoco Mesquita; Flávio Luiz Seixas; Benjamin J W Chow; Claudio Tinoco Mesquita; Ronaldo Altenburg Gismondi
Journal:  Front Cardiovasc Med       Date:  2021-11-11

3.  Retrospective validation of a machine learning clinical decision support tool for myocardial infarction risk stratification.

Authors:  Saarang Panchavati; Carson Lam; Nicole S Zelin; Emily Pellegrini; Gina Barnes; Jana Hoffman; Anurag Garikipati; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  Healthc Technol Lett       Date:  2021-08-31

4.  m6A demethylase FTO regulates the apoptosis and inflammation of cardiomyocytes via YAP1 in ischemia-reperfusion injury.

Authors:  Wei-Liang Ke; Zhi-Wen Huang; Chun-Ling Peng; Yi-Ping Ke
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Machine learning for lymph node metastasis prediction of in patients with gastric cancer: A systematic review and meta-analysis.

Authors:  Yilin Li; Fengjiao Xie; Qin Xiong; Honglin Lei; Peimin Feng
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

6.  [Clinical management in cardiology. Measurement as a means to improvement].

Authors:  José R González-Juanatey; Alejandro Virgós Lamela; José M García-Acuña; Beatriz Pais Iglesias
Journal:  Rev Esp Cardiol       Date:  2020-07-02       Impact factor: 4.753

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.